论文部分内容阅读
目的:观察利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效。方法:回顾分析2015年10月至2016年10月期间在我院治疗的104例2型糖尿病患者临床资料,将其随机分为对照组和观察组,每组52例患者。对照组患者给予二甲双胍治疗,观察组在对照组治疗基础上联合应用利拉鲁肽,对比两组患者临床治疗疗效。结果:观察组患者临床治疗有效率明显高于对照组,空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbAlc)明显低于对照组,胰岛素敏感指数明显高于对照组,差异有统计学意义(P<0.05);治疗和观察期间两组患者临床不良反应发生率差异无统计学意义(P>0.05)。结论:利拉鲁肽联合二甲双胍治疗2型糖尿病临床效果确切,可有效控制血糖水平,且临床用药安全有效,值得推广和应用。
Objective: To observe the clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus. Methods: The clinical data of 104 type 2 diabetic patients treated in our hospital from October 2015 to October 2016 were retrospectively analyzed. They were randomly divided into control group and observation group, with 52 patients in each group. Patients in the control group were treated with metformin. The observation group was treated with liraglutide on the basis of the control group, and the curative effect was compared between the two groups. Results: The effective rate of clinical treatment in the observation group was significantly higher than that in the control group. The fasting blood glucose (FBG), postprandial 2h blood glucose (2hPG) and HbAlc were significantly lower than those in the control group, and the insulin sensitivity index was significantly higher than that of the control group (P <0.05). There was no significant difference in clinical adverse reactions between the two groups during treatment and observation (P> 0.05). Conclusion: The clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus is exact, which can effectively control the blood sugar level. The clinical medication is safe and effective, which is worthy of popularization and application.